Disease on EC 2.1.1.348 - mRNA m6A methyltransferase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Abortion, Spontaneous
The involvement of eukaryotic initiation factor 5A in trophoblast cell function.
Adenocarcinoma
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
Adenocarcinoma
Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Adenocarcinoma of Lung
m6A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma.
Adenocarcinoma of Lung
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Adenocarcinoma of Lung
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
Adenocarcinoma of Lung
SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
Adenocarcinoma of Lung
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.
Adenocarcinoma of Lung
The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by ?-elemene.
Adenomyosis
m6A RNA Methylation Regulators Contribute to Eutopic Endometrium and Myometrium Dysfunction in Adenomyosis.
Alzheimer Disease
Altered Expression of the m6A Methyltransferase METTL3 in Alzheimer's Disease.
Aortic Aneurysm, Abdominal
METTL3 Induces AAA Development and Progression by Modulating N6-Methyladenosine-Dependent Primary miR34a Processing.
Aortic Valve Stenosis
Factors influencing osteogenic differentiation of human aortic valve interstitial cells.
Arthritis, Rheumatoid
Decreased ALKBH5, FTO, and YTHDF2 in Peripheral Blood Are as Risk Factors for Rheumatoid Arthritis.
Arthritis, Rheumatoid
METTL3 Attenuates LPS-Induced Inflammatory Response in Macrophages via NF-?B Signaling Pathway.
Arthritis, Rheumatoid
METTL3 Promotes Activation and Inflammation of FLSs Through the NF-?B Signaling Pathway in Rheumatoid Arthritis.
Asthenozoospermia
Increased N6-methyladenosine in Human Sperm RNA as a Risk Factor for Asthenozoospermia.
Atherosclerosis
METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications.
Atherosclerosis
METTL14 mediated m6A modification to LncRNA ZFAS1/ RAB22A: A novel therapeutic target for atherosclerosis.
Atherosclerosis
METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium.
Bacterial Infections
N6-Adenosine Methylation of Socs1 mRNA Is Required to Sustain the Negative Feedback Control of Macrophage Activation.
Bacterial Infections
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
Bone Resorption
Circ_0008542 in osteoblast exosomes promotes osteoclast-induced bone resorption through m6A methylation.
Bone Resorption
YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-?B and MAPK signaling pathways.
Breast Neoplasms
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
Breast Neoplasms
CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression.
Breast Neoplasms
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
Breast Neoplasms
HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Breast Neoplasms
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Breast Neoplasms
Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway.
Breast Neoplasms
METTL14 promotes the migration and invasion of breast cancer cells by modulating N6?methyladenosine and hsa?miR?146a?5p expression.
Breast Neoplasms
METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
Breast Neoplasms
N6 -Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis.
Breast Neoplasms
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Breast Neoplasms
N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.
Breast Neoplasms
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
Breast Neoplasms
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Breast Neoplasms
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Carcinogenesis
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
Carcinogenesis
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Carcinogenesis
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Carcinogenesis
Detailed modeling of positive selection improves detection of cancer driver genes.
Carcinogenesis
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Carcinogenesis
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Carcinogenesis
EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.
Carcinogenesis
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Carcinogenesis
Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma.
Carcinogenesis
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Carcinogenesis
m6A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways.
Carcinogenesis
Methyltransferase-like 3-induced N6-methyladenosine upregulation promotes oral squamous cell carcinoma by through p38.
Carcinogenesis
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Carcinogenesis
METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
Carcinogenesis
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
Carcinogenesis
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
Carcinogenesis
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
Carcinogenesis
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Carcinogenesis
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
Carcinogenesis
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
Carcinogenesis
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Carcinogenesis
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
Carcinogenesis
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
Carcinogenesis
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
Carcinogenesis
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Carcinogenesis
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
Carcinogenesis
METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Carcinogenesis
Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers.
Carcinogenesis
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
Carcinogenesis
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Carcinogenesis
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer.
Carcinogenesis
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Carcinogenesis
RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.
Carcinogenesis
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
Carcinogenesis
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Carcinogenesis
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
Carcinogenesis
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Carcinogenesis
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
Carcinogenesis
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Carcinoma
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Carcinoma
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Carcinoma
Identification of METTL14 in Kidney Renal Clear Cell Carcinoma Using Bioinformatics Analysis.
Carcinoma
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
Carcinoma
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
Carcinoma
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
Carcinoma
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Carcinoma
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
Carcinoma
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
Carcinoma
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
Carcinoma
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Carcinoma
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
Carcinoma
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
Carcinoma
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Carcinoma
Prognostic Roles of N6-Methyladenosine METTL3 in Different Cancers: A System Review and Meta-Analysis.
Carcinoma
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
Carcinoma
The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation.
Carcinoma
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
Carcinoma
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
Carcinoma
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
Carcinoma
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
Carcinoma
[Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits cell proliferation and promotes apoptosis in cervical cancer cells].
Carcinoma, Hepatocellular
Correction to: YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner.
Carcinoma, Hepatocellular
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
Carcinoma, Hepatocellular
METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.
Carcinoma, Hepatocellular
METTL3 promotes the progression of hepatocellular carcinoma through m6A-mediated up-regulation of microRNA-873-5p.
Carcinoma, Hepatocellular
MicroRNA-145 Modulates N(6)-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N(6)-Methyladenosine Binding YTH Domain Family 2 Protein.
Carcinoma, Hepatocellular
RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.
Carcinoma, Hepatocellular
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Carcinoma, Hepatocellular
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
The Effect of m6A Methylation Regulatory Factors on the Malignant Progression and Clinical Prognosis of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
Carcinoma, Hepatocellular
USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization.
Carcinoma, Hepatocellular
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Carcinoma, Hepatocellular
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Carcinoma, Hepatocellular
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
Carcinoma, Hepatocellular
[METTL14 as a predictor of postoperative survival outcomes of patients with hepatocellular carcinoma].
Carcinoma, Non-Small-Cell Lung
MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
Carcinoma, Non-Small-Cell Lung
SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
Carcinoma, Ovarian Epithelial
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Carcinoma, Ovarian Epithelial
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Carcinoma, Renal Cell
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Carcinoma, Renal Cell
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
Carcinoma, Squamous Cell
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Carcinoma, Squamous Cell
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
Carcinoma, Squamous Cell
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
Cardiomegaly
De-ubiquitination of p300 by USP12 Critically Enhances METTL3 Expression and Ang II-induced cardiac hypertrophy.
Cataract
N6-Methyladenosine METTL3 Modulates the Proliferation and Apoptosis of Lens Epithelial Cells in Diabetic Cataract.
Colitis
A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells.
Colonic Neoplasms
An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells.
Colonic Neoplasms
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Colorectal Neoplasms
Knockdown of RNA N6-methyladenosine methyltransferase METTL3 represses Warburg effect in colorectal cancer via regulating HIF-1?.
Colorectal Neoplasms
LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer.
Colorectal Neoplasms
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Colorectal Neoplasms
m6A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways.
Colorectal Neoplasms
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Colorectal Neoplasms
Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner.
Colorectal Neoplasms
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Colorectal Neoplasms
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
Colorectal Neoplasms
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Colorectal Neoplasms
N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
Colorectal Neoplasms
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
Colorectal Neoplasms
RNA m6A methyltransferase METTL3 promotes colorectal cancer cell proliferation and invasion by regulating Snail expression.
Colorectal Neoplasms
RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.
Colorectal Neoplasms
The differentiation of colorectal cancer is closely relevant to m6A modification.
Colorectal Neoplasms
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Colorectal Neoplasms
Upregulation of circular and linear METTL3 and USP3 in colorectal cancer.
Corneal Neovascularization
Role of METTL3-Dependent N6-Methyladenosine mRNA Modification in the Promotion of Angiogenesis.
COVID-19
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication.
COVID-19
METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection.
COVID-19
Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication.
Cytomegalovirus Infections
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Diabetes Mellitus
Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8.
Diabetes Mellitus, Type 2
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Diabetic Nephropathies
METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of ?-klotho.
Diabetic Retinopathy
Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Endometrial Neoplasms
Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
Endometrial Neoplasms
YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A.
Endometriosis
Inhibition of METTL3/m6A/miR126 promotes the migration and invasion of endometrial stromal cells in endometriosis.
Esophageal Neoplasms
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
Esophageal Neoplasms
Network analysis of miRNA targeting m6A-related genes in patients with esophageal cancer.
Esophageal Neoplasms
Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer.
Esophageal Squamous Cell Carcinoma
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
Esophageal Squamous Cell Carcinoma
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
Esophageal Squamous Cell Carcinoma
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
Esophageal Squamous Cell Carcinoma
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
Gastrointestinal Neoplasms
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.
Glioblastoma
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism.
Glioblastoma
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Glioblastoma
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
Glioblastoma
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Glioma
A Risk Signature Consisting of Eight m6A Methylation Regulators Predicts the Prognosis of Glioma.
Glioma
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Glioma
Genetic variants in m6A modification core genes are associated with glioma risk in Chinese children.
Glioma
m6A RNA Methylation Controls Proliferation of Human Glioma Cells by Influencing Cell Apoptosis.
Glioma
METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-?B to promote the malignant progression of IDH-wildtype glioma.
Glioma
METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner.
Glioma
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
Glioma
N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling.
Glioma
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-?B and promote the malignant progression of glioma.
Glucose Intolerance
Acute Deletion of METTL14 in ?-Cells of Adult Mice Results in Glucose Intolerance.
Heart Failure
The N6-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy.
Hematologic Neoplasms
Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion.
Hemorrhoids
MiR-4729 regulates TIE1 mRNA m6A modification and angiogenesis in hemorrhoids by targeting METTL14.
Hepatoblastoma
Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/?-catenin signalling pathway.
Hepatoblastoma
m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma.
Hepatoblastoma
Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children: A seven-center case-control study.
Herpesviridae Infections
N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection.
Hypersensitivity
Methyltransferase-like 3 contributes to inflammatory pain by targeting TET1 in YTHDF2-dependent manner.
Hypertension
The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension.
Infections
Enterotoxigenic Escherichia coli infection promotes enteric defensin expression via FOXO6-METTL3-m6A-GPR161 signalling axis.
Infections
Knockdown of METTL3 inhibits enterovirus 71-induced apoptosis of mouse Schwann cell through regulation of autophagy.
Infections
Metal-Protein Nanoparticles Facilitate Anti-VSV and H1N1 Viruses Through the Coordinative Actions on Innate Immune Responses and METTL14.
Infections
N6-methyladenosine modifications enhance enterovirus 71 ORF translation through METTL3 cytoplasmic distribution.
Infections
N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA.
Infections
Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication.
Infertility
The RNA m(6)A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence.
Influenza, Human
Metal-Protein Nanoparticles Facilitate Anti-VSV and H1N1 Viruses Through the Coordinative Actions on Innate Immune Responses and METTL14.
Insulin Resistance
METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
Insulin Resistance
METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice.
Intracranial Arteriovenous Malformations
N6-methyladenosine methyltransferase METTL3 affects the phenotype of cerebral arteriovenous malformation via modulating Notch signaling pathway.
Kidney Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Lentivirus Infections
RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum.
Leukemia
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Leukemia
YTHDF2 is a potential target of AML1/ETO-HIF1? loop-mediated cell proliferation in t(8;21) AML.
Leukemia, Myeloid
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Leukemia, Myeloid
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Leukemia, Myeloid, Acute
Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Novel METTL3 Modulators for Treating Acute Myeloid Leukemia (AML).
Leukemia, Myeloid, Acute
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Leukemia, Myeloid, Acute
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Liver Neoplasms
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
Liver Neoplasms
RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.
Liver Neoplasms
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Liver Neoplasms
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Liver Neoplasms
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Lung Neoplasms
Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
Lung Neoplasms
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Lung Neoplasms
METTL3?mediated m6A modification of Bcl?2 mRNA promotes non?small cell lung cancer progression.
Lung Neoplasms
miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer.
Lung Neoplasms
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.
Lung Neoplasms
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Lung Neoplasms
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
Lung Neoplasms
Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Lung Neoplasms
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.
Lung Neoplasms
The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB.
Lung Neoplasms
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Lung Neoplasms
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
Lupus Erythematosus, Systemic
The study of METTL14, ALKBH5, and YTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus.
Lymphatic Metastasis
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Lymphatic Metastasis
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Lymphatic Metastasis
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
Lymphatic Metastasis
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
Lymphatic Metastasis
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Lymphatic Metastasis
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Lymphatic Metastasis
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Lymphatic Metastasis
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Melanoma
Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma.
Melanoma
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
Melanoma
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Melanoma
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation.
Melanoma
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
Melanoma
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
Melanoma
RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2.
Microphthalmos
m6A writer complex promotes timely differentiation and survival of retinal progenitor cells in zebrafish.
Mouth Neoplasms
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
mrna m6a methyltransferase deficiency
A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells.
mrna m6a methyltransferase deficiency
Acute Deletion of METTL14 in ?-Cells of Adult Mice Results in Glucose Intolerance.
mrna m6a methyltransferase deficiency
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
mrna m6a methyltransferase deficiency
Interplay of m6A and H3K27 trimethylation restrains inflammation during bacterial infection.
mrna m6a methyltransferase deficiency
METTL14 is essential for ?-cell survival and insulin secretion.
mrna m6a methyltransferase deficiency
METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes.
mrna m6a methyltransferase deficiency
Mettl3 Deficiency Sustains Long-Chain Fatty Acid Absorption through Suppressing Traf6-Dependent Inflammation Response.
mrna m6a methyltransferase deficiency
METTL3 Induces AAA Development and Progression by Modulating N6-Methyladenosine-Dependent Primary miR34a Processing.
mrna m6a methyltransferase deficiency
METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export.
mrna m6a methyltransferase deficiency
METTL3-dependent m6A modification programs T follicular helper cell differentiation.
mrna m6a methyltransferase deficiency
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
mrna m6a methyltransferase deficiency
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
mrna m6a methyltransferase deficiency
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
mrna m6a methyltransferase deficiency
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
mrna m6a methyltransferase deficiency
The RNA m(6)A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence.
mrna m6a methyltransferase deficiency
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Myocardial Infarction
Loss of m6A methyltransferase METTL3 promotes heart regeneration and repair after myocardial injury.
Myocardial Infarction
Silencing of METTL3 attenuates cardiac fibrosis induced by myocardial infarction via inhibiting the activation of cardiac fibroblasts.
Nasopharyngeal Carcinoma
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Nasopharyngeal Carcinoma
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Nasopharyngeal Carcinoma
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Neoplasm Metastasis
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
Neoplasm Metastasis
Circular RNA circ_0001105 Inhibits Progression and Metastasis of Osteosarcoma by Sponging miR-766 and Activating YTHDF2 Expression.
Neoplasm Metastasis
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Neoplasm Metastasis
Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
Neoplasm Metastasis
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Neoplasm Metastasis
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Neoplasm Metastasis
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.
Neoplasm Metastasis
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Neoplasm Metastasis
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
Neoplasm Metastasis
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
Neoplasm Metastasis
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Neoplasm Metastasis
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Neoplasm Metastasis
METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner.
Neoplasm Metastasis
METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing.
Neoplasm Metastasis
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Neoplasm Metastasis
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
Neoplasm Metastasis
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Neoplasm Metastasis
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
Neoplasm Metastasis
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
Neoplasm Metastasis
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Neoplasm Metastasis
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
Neoplasm Metastasis
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
Neoplasm Metastasis
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Neoplasm Metastasis
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Neoplasm Metastasis
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
Neoplasm Metastasis
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
Neoplasm Metastasis
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
Neoplasm Metastasis
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Neoplasm Metastasis
METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.
Neoplasm Metastasis
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Neoplasm Metastasis
N6 -Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis.
Neoplasm Metastasis
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
Neoplasm Metastasis
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Neoplasm Metastasis
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Neoplasm Metastasis
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
Neoplasm Metastasis
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.
Neoplasm Metastasis
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Neoplasm Metastasis
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Neoplasm Metastasis
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Neoplasm Metastasis
The biological function of m6A reader YTHDF2 and its role in human disease.
Neoplasm Metastasis
The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma.
Neoplasm Metastasis
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Neoplasm Metastasis
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
Neoplasm Metastasis
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Neoplasm Metastasis
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Neoplasm Metastasis
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer.
Neoplasm Metastasis
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Neoplasms
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Neoplasms
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
Neoplasms
Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine-centre case-control study.
Neoplasms
Author Correction: METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
Neoplasms
Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Neoplasms
CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression.
Neoplasms
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
Neoplasms
Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases.
Neoplasms
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
Neoplasms
Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer.
Neoplasms
Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression.
Neoplasms
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Neoplasms
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Neoplasms
Detailed modeling of positive selection improves detection of cancer driver genes.
Neoplasms
Development and validation of a m6A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma.
Neoplasms
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Neoplasms
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
Neoplasms
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Neoplasms
EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.
Neoplasms
Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.
Neoplasms
Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells.
Neoplasms
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Neoplasms
Expression patterns and prognostic value of m6A-related genes in colorectal cancer.
Neoplasms
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
Neoplasms
HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Neoplasms
Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma.
Neoplasms
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Neoplasms
Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Neoplasms
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Neoplasms
Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures.
Neoplasms
m(6)A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination.
Neoplasms
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
Neoplasms
m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
Neoplasms
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Neoplasms
m6A methyltransferase METTL3 promotes retinoblastoma progression via PI3K/AKT/mTOR pathway.
Neoplasms
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
Neoplasms
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
Neoplasms
m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma.
Neoplasms
m6A RNA methylation regulators have prognostic value in papillary thyroid carcinoma.
Neoplasms
m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
Neoplasms
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Neoplasms
Methyltransferase-like 3-induced N6-methyladenosine upregulation promotes oral squamous cell carcinoma by through p38.
Neoplasms
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
Neoplasms
METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study.
Neoplasms
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Neoplasms
METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation.
Neoplasms
METTL14 promotes the migration and invasion of breast cancer cells by modulating N6?methyladenosine and hsa?miR?146a?5p expression.
Neoplasms
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Neoplasms
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
Neoplasms
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Neoplasms
METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation.
Neoplasms
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
Neoplasms
METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.
Neoplasms
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
Neoplasms
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
Neoplasms
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
Neoplasms
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation.
Neoplasms
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
Neoplasms
METTL3 polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study.
Neoplasms
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Neoplasms
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
Neoplasms
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
Neoplasms
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
Neoplasms
METTL3 promotes the progression of hepatocellular carcinoma through m6A-mediated up-regulation of microRNA-873-5p.
Neoplasms
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Neoplasms
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
Neoplasms
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Neoplasms
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
Neoplasms
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Neoplasms
METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B.
Neoplasms
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
Neoplasms
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
Neoplasms
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
Neoplasms
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Neoplasms
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
Neoplasms
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
Neoplasms
METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells.
Neoplasms
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Neoplasms
METTL3-mediated RNA m6A hypermethylation promotes tumorigenesis and GH secretion of pituitary somatotroph adenomas.
Neoplasms
METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.
Neoplasms
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Neoplasms
MicroRNA-145 Modulates N(6)-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N(6)-Methyladenosine Binding YTH Domain Family 2 Protein.
Neoplasms
Mobile element insertions and associated structural variants in longitudinal breast cancer samples.
Neoplasms
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.
Neoplasms
Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers.
Neoplasms
N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
Neoplasms
N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma.
Neoplasms
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Neoplasms
N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
Neoplasms
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Neoplasms
N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.
Neoplasms
N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
Neoplasms
N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer.
Neoplasms
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
Neoplasms
Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.
Neoplasms
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Neoplasms
Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Neoplasms
Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children: A seven-center case-control study.
Neoplasms
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
Neoplasms
Prognostic Roles of N6-Methyladenosine METTL3 in Different Cancers: A System Review and Meta-Analysis.
Neoplasms
Regulation of telomere homeostasis and genomic stability in cancer by N 6-adenosine methylation (m6A).
Neoplasms
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.
Neoplasms
RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.
Neoplasms
RNA m6A methyltransferase METTL3 promotes colorectal cancer cell proliferation and invasion by regulating Snail expression.
Neoplasms
RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.
Neoplasms
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
Neoplasms
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
Neoplasms
RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy.
Neoplasms
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Neoplasms
Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Neoplasms
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
Neoplasms
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Neoplasms
SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
Neoplasms
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
Neoplasms
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
Neoplasms
The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in hepatocellular carcinoma.
Neoplasms
The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance.
Neoplasms
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth.
Neoplasms
The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
Neoplasms
The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma.
Neoplasms
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Neoplasms
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Neoplasms
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
Neoplasms
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
Neoplasms
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Neoplasms
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Neoplasms
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Neoplasms
The role of N6-methyladenosine RNA methylation in the heat stress response of sheep (Ovis aries).
Neoplasms
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
Neoplasms
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Neoplasms
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Neoplasms
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Neoplasms
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-?B and promote the malignant progression of glioma.
Neoplasms
YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A.
Neoplasms
YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.
Neoplasms
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Neoplasms
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Neoplasms
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Neoplasms
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
Neoplasms
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
Neoplasms
[METTL14 as a predictor of postoperative survival outcomes of patients with hepatocellular carcinoma].
Neoplasms, Germ Cell and Embryonal
METTL3 May Regulate Testicular Germ Cell Tumors Through EMT and Immune Pathways.
Neoplasms, Germ Cell and Embryonal
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Neuroblastoma
Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine-centre case-control study.
Neuroblastoma
METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study.
Non-alcoholic Fatty Liver Disease
METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease.
Obesity
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
Obesity
METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice.
Obesity
Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation.
Osteoarthritis
METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response.
Osteoarthritis
METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte.
Osteoporosis
m6A Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells.
Osteoporosis
Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis.
Osteoporosis
Regulatory Role of RNA N6-Methyladenosine Modification in Bone Biology and Osteoporosis.
Osteosarcoma
Circular RNA circ_0001105 Inhibits Progression and Metastasis of Osteosarcoma by Sponging miR-766 and Activating YTHDF2 Expression.
Osteosarcoma
m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma.
Osteosarcoma
METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation.
Osteosarcoma
Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Osteosarcoma
The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Ovarian Neoplasms
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.
Ovarian Neoplasms
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
Ovarian Neoplasms
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
Ovarian Neoplasms
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ovarian Neoplasms
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
Ovarian Neoplasms
METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Ovarian Neoplasms
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Pancreatic Neoplasms
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Pancreatic Neoplasms
Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells.
Pancreatic Neoplasms
m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
Pancreatic Neoplasms
Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Pancreatic Neoplasms
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
Pancreatic Neoplasms
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Pancreatic Neoplasms
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer.
Parkinsonian Disorders
Sex differences in autophagy-mediated diseases: toward precision medicine.
Pituitary Neoplasms
METTL3-mediated RNA m6A hypermethylation promotes tumorigenesis and GH secretion of pituitary somatotroph adenomas.
Pneumonia
METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2.
Polycystic Kidney, Autosomal Dominant
A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.
Pre-Eclampsia
Upregulation of METTL3 expression and m6A RNA methylation in placental trophoblasts in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.
Prostatic Neoplasms
Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Prostatic Neoplasms
m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Prostatic Neoplasms
Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance.
Prostatic Neoplasms
RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.
Prostatic Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Prostatic Neoplasms
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Prostatic Neoplasms
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Pulmonary Arterial Hypertension
The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
m6A RNA methylation regulators could contribute to the occurrence of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
Pulmonary Fibrosis
m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation.
Rectal Neoplasms
M6A "Writer" Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer.
Rectal Neoplasms
Prognostic Implication of the m6A RNA Methylation Regulators in Rectal Cancer.
Reperfusion Injury
METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation.
Reperfusion Injury
The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1.
Retinoblastoma
m6A methyltransferase METTL3 promotes retinoblastoma progression via PI3K/AKT/mTOR pathway.
Seminoma
METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma.
Seminoma
The m6A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma.
Severe Acute Respiratory Syndrome
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication.
Squamous Cell Carcinoma of Head and Neck
Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
Squamous Cell Carcinoma of Head and Neck
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Squamous Cell Carcinoma of Head and Neck
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Starvation
Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment.
Stomach Neoplasms
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Stomach Neoplasms
Inhibiting PP2Ac? Promotes the Malignant Phenotype of Gastric Cancer Cells through the ATM/METTL3 Axis.
Stomach Neoplasms
Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation.
Stomach Neoplasms
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
Stomach Neoplasms
METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
Stomach Neoplasms
METTL3-mediated m6A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2.
Stomach Neoplasms
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
Stomach Neoplasms
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Stomach Neoplasms
MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).
Stomach Neoplasms
MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62.
Stomach Neoplasms
N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer.
Stomach Neoplasms
The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
Stomach Neoplasms
YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.
Testicular Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Thymoma
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Thymus Neoplasms
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Thyroid Cancer, Papillary
METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
Thyroid Cancer, Papillary
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
Thyroid Diseases
METTL3 gene polymorphisms contribute to susceptibility to autoimmune thyroid disease.
Thyroid Neoplasms
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
Thyroid Neoplasms
Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m6A Methylation on TCF1.
Tics
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Triple Negative Breast Neoplasms
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
Triple Negative Breast Neoplasms
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Triple Negative Breast Neoplasms
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
Urinary Bladder Neoplasms
Corrigendum: Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Urinary Bladder Neoplasms
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Urinary Bladder Neoplasms
Detailed modeling of positive selection improves detection of cancer driver genes.
Urinary Bladder Neoplasms
Dynamic m6A mRNA methylation reveals the role of METTL3-m6A-CDCP1 signaling axis in chemical carcinogenesis.
Urinary Bladder Neoplasms
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Urinary Bladder Neoplasms
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Urinary Bladder Neoplasms
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer.
Urinary Bladder Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Urinary Bladder Neoplasms
The m6A Methylation-Regulated AFF4 Promotes Self-Renewal of Bladder Cancer Stem Cells.
Urinary Bladder Neoplasms
The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-?B/MYC signaling network.
Urologic Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Uterine Cervical Neoplasms
Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer.
Uterine Cervical Neoplasms
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Uterine Cervical Neoplasms
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
Uterine Cervical Neoplasms
METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B.
Uterine Cervical Neoplasms
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
Uterine Cervical Neoplasms
N6-methyladenosine regulates glycolysis of cancer cells through PDK4.
Uterine Cervical Neoplasms
[Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits cell proliferation and promotes apoptosis in cervical cancer cells].
Vascular Calcification
METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate.
Vascular Calcification
miR-33a-5p Suppresses ox-LDL-Stimulated Calcification of Vascular Smooth Muscle Cells by Targeting METTL3.
Vesicular Stomatitis
N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA.
Virus Diseases
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Virus Diseases
m6A modification controls the innate immune response to infection by targeting type I interferons.
Vitreoretinopathy, Proliferative
METTL3 attenuates proliferative vitreoretinopathy and epithelial-mesenchymal transition of retinal pigment epithelial cells via wnt/?-catenin pathway.
Wilms Tumor
Human umbilical cord mesenchymal stem cells deliver exogenous miR-26a-5p via exosomes to inhibit nucleus pulposus cell pyroptosis through METTL14/NLRP3.
Wilms Tumor
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
Wilms Tumor
METTL3 polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study.
Wilms Tumor
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Wilms Tumor
N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells.
Wilms Tumor
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Wilms Tumor
The contribution of YTHDF2 gene rs3738067 A>G to the Wilms tumor susceptibility.
Wilms Tumor
The RNA Methyltransferase Complex of WTAP, METTL3, and METTL14 Regulates Mitotic Clonal Expansion in Adipogenesis.
Zika Virus Infection
Dynamics of Human and Viral RNA Methylation during Zika Virus Infection.
html completed